In a phase II trial of AZD4547 in patients with advanced cancers with FGFR1–3 aberrations, PRs were observed in 4 of 48 (8%) patients, including 2 patients with FGFR mutations and 2 with FGFR3–TACC3 fusions [63]. This evidence concerns the gene TACC3 and cancer.